Current and future applications of liquid biopsy in nonsmall cell lung cancer from early to advanced stages. (12th February 2020)

• Record Type: Journal Article
• Authors: Guibert, Nicolas; Pradines, Anne; Favre, Gilles; Mazieres, Julien
• Is Part Of: European respiratory review. Volume 29:Number 155(2020)
• Publication Date: 2020-02-12
• Subjects: Respiratory organs -- Diseases -- Periodicals; Respiratory Tract Diseases; Respiratory organs -- Diseases; Respiratory organs -- Diseases -- Treatment; Electronic journals; Periodical; Periodicals; Periodicals; 616.2
• DOI: 10.1183/16000617.0052-2019
• Languages: English
• ISSNs: 0905-9180

Abstract

Liquid biopsy refers to the analysis of any tumour-derived material circulating in the blood or any other body fluid. This concept is particularly relevant in lung cancer as the tumour is often difficult to reach and may need an invasive and potentially harmful procedure. Moreover, the multitude of anticancer drugs and their sequential use underline the importance of conducting an iterative assessment of tumour biology. Liquid biopsies can noninvasively detect any targetable genomic alteration and guide corresponding targeted therapy, in addition to monitoring response to treatment and exploring the genetic changes at resistance, overcoming spatial and temporal heterogeneity. In this article, we review the available data in the field, which suggest the potential of liquid biopsy in the area of lung cancer, with a particular focus on cell-free DNA and circulating tumour cells. We discuss their respective applications in patient selection and monitoring through targeted therapy, as well as immune checkpoint inhibitors. The current data and future applications of liquid biopsy in the early stage setting are also investigated. Liquid biopsy has the potential to help manage nonsmall cell lung cancer throughout all stages of lung cancer: screening, minimal residual disease detection to guide adjuvant treatment, early detection of relapse, systemic treatment initiation and monitoring of response (targeted or immune therapy), and resistance genotyping. Liquid biopsy has great potential for NSCLC screening, for treatment selection (adjuvant, targeted therapy and immunotherapy), to monitor response to treatment and to analyse and overcome acquired resistance http://bit.ly/2m26HGm